BioSpace News Archive

Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and full year 2022 operating results on Tuesday, February 28, 2023, after market close.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer and Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will participate virtually in the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023, at 11:20 a.m. ET.

Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the Company has been granted a clinical Type B meeting with the U.S. Food & Drug Administration (FDA).

Impact BioMedical, in concert with its research partner Global Research and Discovery Group, find themselves in the right place at the right time as the biomedical investment industry shifts toward Discovery-phase funding in biomedical research, licensing and intellectual property and away from waiting until Phase 2 or Phase 3 clinical trials.

BioStem Technologies Inc., announced that it has entered into a Share Exchange Agreement with M.W.

Masimo (NASDAQ: MASI) will release fourth quarter and FY 2022 financial results for the period ended December 31, 2022, after the market closes on Tuesday, February 28, 2023.

enGene Inc., a clinical-stage biotechnology company pioneering non-viral gene therapies for local administration to mucosal tissues enabled by its proprietary DDX platform, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium being held from February 16th to 18th, 2023.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it has received an exemption under Section 56 of the Controlled Drugs and Substances Act

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD)